|
Mar 14
|
Taysha Gene Therapies to Release Full-Year 2023 Financial Results, Provide Corporate and Clinical Updates and Host Conference Call on March 19
|
|
Jan 15
|
3 Growth Stocks That Could Go Parabolic in 2024
|
|
Jan 10
|
Taysha Gene Therapies Announces First Pediatric Patient Dosed with TSHA-102 in REVEAL Phase 1/2 Pediatric Trial in Rett Syndrome
|
|
Dec 19
|
Trinity Capital Inc. Provides $40 Million Term Loan to Taysha Gene Therapies
|
|
Nov 29
|
Taysha Gene Therapies Announces Expanded Eligibility in REVEAL Phase 1/2 Adult Trial to Include Adolescent Rett Syndrome Patients
|
|
Sep 26
|
Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome
|
|
Jul 18
|
Taysha Gene Therapies Insiders Added US$3.0m Of Stock To Their Holdings
|